APAC Gene Therapy for Hemophilia Market Industry Trends and Forecast to 2034: Segmented by (Type, Vector, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
APAC · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$90.9 MnPlaceholder estimate
Estimate 2025$119.5 Mn23.6% of the global market
Projected 2034$1.40 Bn 1,075.8%Adds $1.29 Bn over 9 forecast years
CAGR 2025–203431.5%Faster than 97% of 180 Pharmaceuticals markets here
Key players5
APAC is 23.57% of the global market.
Among regions, the largest is North America at $257.1 Mn.
BioMarin, CSL Behring, Pfizer Inc., Roche, Sangamo Therapeutics (see all)
Active clinical trials
15 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The APAC Gene Therapy for Hemophilia Market Analysis Executive Summary
Gene therapies for hemophilia give patients a working copy of the clotting factor gene, so they may need fewer or no regular infusions.
Key segments of the gene Therapy for Hemophilia market include type (Hemophilia A and Hemophilia B) and vector (AAV5 and AAV Other Serotypes).
Asia Pacific Gene Therapy for Hemophilia market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
APAC Gene Therapy for Hemophilia Market Dynamics
Market Growth Drivers
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the gene Therapy for Hemophilia market.
Opportunity
Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the gene Therapy for Hemophilia market.
Market Restraints
Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the gene Therapy for Hemophilia market. Payers are still working out how to pay for one-time cures.
Competitive Landscape for Gene Therapy for Hemophilia Market in APAC
The gene Therapy for Hemophilia market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Gene Therapy for Hemophilia Market in APAC
Gene Therapy for Hemophilia in APAC: rules, payment and research
In some of the countries we cover here, medicines are approved by TGA (Australia)[1], NMPA (China)[2], Drug Office (Hong Kong)[3], CDSCO (India)[4], PMDA (Japan)[5], NPRA (Malaysia)[6], Medsafe (New Zealand)[7], FDA Philippines (Philippines)[8], HSA (Singapore)[9] and Thai FDA (Thailand)[10]. How care is paid for in some of these countries: Medicare and the PBS (Australia)[11], basic medical insurance (China)[12], the Hospital Authority (Hong Kong)[13], Ayushman Bharat PM-JAY (India)[14], public health insurance (Japan)[15], subsidised public care (Malaysia)[16], Pharmac (New Zealand)[17], PhilHealth (Philippines)[18], MediShield Life (Singapore)[19] and the Universal Coverage Scheme (Thailand)[20]. ClinicalTrials.gov lists 15 studies on Gene Therapy for Hemophilia that are recruiting, active or about to start in APAC.[21]
[21]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for gene Therapy for Hemophilia. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Type
4.2 By Vector
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 BioMarin
7.2 CSL Behring
7.3 Pfizer
7.4 Roche
7.5 Sangamo Therapeutics
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The gene Therapy for Hemophilia market can be segmented based on various criteria, including type, vector and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Gene Therapy for Hemophilia right now, from free public sources.
Clinical trials
15 active trials in China, India, Japan, Australia, Hong Kong, Philippines, Singapore, Thailand, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan
Recruiting, about to start, or running now. Counted across the 16 countries we report on in APAC.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
How big is the Gene Therapy for Hemophilia market in Asia Pacific?
Placeholder estimate: about $119.5 Mn in 2025, rising to about $1.40 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Gene Therapy for Hemophilia market in Asia Pacific growing?
Placeholder estimate: about 31.5% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Gene Therapy for Hemophilia market report cover?
The report splits the market by type (Hemophilia A, Hemophilia B), vector (AAV5, AAV Other Serotypes) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Gene Therapy for Hemophilia market?
Key players include BioMarin, CSL Behring, Pfizer Inc., Roche and Sangamo Therapeutics.
What is driving the Gene Therapy for Hemophilia market?
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the gene Therapy for Hemophilia market.
How many clinical trials on Gene Therapy for Hemophilia are running in Asia Pacific?
15 studies are recruiting, active or about to start in Asia Pacific, counted across the 16 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
How much research is published on Gene Therapy for Hemophilia?
PubMed lists 291 papers on Gene Therapy for Hemophilia added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.